Dimethylation of adenine 2058 in 23S rRNA renders bacteria resistant to macrolides, lincosamides, and streptogramin B (MLS resistance), because the antibiotic binding site on the altered 50S ribosomal subunit is no longer accessible. We now report that certain 6-O-methyl-11,12-cyclic carbamate derivatives of erythromycin are able to bind to dimethylated MLS-resistant 50S ribosomal subunits, thus inhibiting protein synthesis and cell growth. One of these novel structures, an 11-deoxy-11-(carboxyamino)-6-O-methylerythromycin A 11,12-(cyclic ester) derivative, structure la, was studied in detail. It inhibited in vitro protein synthesis in extracts prepared from both susceptible and MLS-resistant Bacillus subtilis with 50% inhibitory concentrations of 0.4 and 20 ,uM, respectively. The derivative bound specifically to a single site on the 50S subunit of MLS-resistant ribosomes prepared from B. subtilis and Staphylococcus aureus, and no binding to 30S subunits was observed. The association rate constant of derivative la with sensitive and resistant ribosomes was 100-and 500-fold slower, respectively, than that of the parent compound, erythromycin, with sensitive ribosomes. The dissociation rate constant of la from sensitive and resistant ribosomes was 50-to 100-fold slower than the rate of erythromycin dissociation from sensitive ribosomes. Furthermore, la binding to sensitive 50S subunits led to induction of ermC and ermD, while binding to resistant 50S subunits did not, showing that perturbation of sensitive and resistant 50S subunit function by la differs. These data demonstrated that la is unique in its interaction with MLS-resistant ribosomes and that this interaction causes a novel allosteric perturbation of ribosome function.
There are several theoretical mechanisms by which bacteria could exhibit resistance to the inhibitory effects of macrolide antibiotics. These fall into four classes: (i) lack of macrolide entrance into the cell, (ii) chemical inactivation of the macrolide, (iii) lack of binding of the macrolide to the ribosome target, and (iv) lack of an inhibitory response upon binding to the ribosome target. Evidence for the existence of actual mechanisms falling into classes i to iii has been published (see below), and the most definitive studies concern mechanisms from classes ii and iii. The only report of a class iv mechanism of resistance concerns erythromycindependent growth of Escherichia coli containing the mac allele (31, 35) .
Several reports suggest that resistance to macrolides can involve lack of entrance into the cell of either macrolide producers (11) or bacterial pathogens (16, 34) . However, there are also studies which demonstrate that macrolides (specifically erythromycin) enter into cells by passive diffusion of the un-ionized form across the lipid bilayer of the cell membrane (7, 27) . Thus, accumulation is temperature dependent due to phase changes in the lipid bilayer and energy independent (7, 27) , and in the absence of access to the intracellular binding site (using macrolide-lincosamide-streptogramin B [MLS]-resistant bacteria), drug does not accumulate, but rather only equilibrates with the extracellular drug concentration (R. C. Goldman, unpublished observations). It would thus appear difficult to reconcile these data with a mechanism of resistance due to lack of passive diffusion across the lipid bilayer. Since none of the studies suggesting resistance due to lack of drug entrance into the cell have concurrently demonstrated the mechanism in-volved, further studies are required before these observations can be generally accepted. In contrast, resistance due to drug modification is well documented. Degradation of macrolides by plasmid-coded esterases renders the drug inactive and imparts resistance to bacteria carrying such genes, designated ere (1) . In addition, various macrolides are phosphorylated on the 2'-hydroxyl group by extracts of Streptomyces coelicolor (36) , and recently a similar enzymatic activity was found in a clinical isolate of Escherichia coli (25) .
Although macrolide resistance can occur due to lowfrequency mutational changes in ribosomal proteins (29) in laboratory strains, the most frequent form of resistance observed clinically is MLS resistance (9) . The mechanism involves enzymatic dimethylation (15) of adenine 2058 in the 23S rRNA sequence (30) by a specific methylase, resulting in 50S ribosomal subunits which will not bind the antibiotics; however, the exact structural mechanism by which dimethylation precludes binding is unknown, as is the stage in ribosome synthesis and assembly when dimethylation occurs in vivo. Expression of the methylase gene can be constitutive or inducible at the level of translational control (8, 33) . In either case, constitutive or inducible expression, dimethylation alters ribosome structure in a manner which precludes antibiotic binding. The methylase genes (erm genes) apparently arose in antibiotic producers and subsequently spread to both gram-negative and gram-positive bacterial pathogens (2) .
The two logical approaches to overcoming MLS resistance are inhibiting dimethylation (somewhat analogous to inhibitors of 1-lactamase) and modifying the antibiotic so as to regain access to the structurally modified ribosomal binding site. We Selection of a pE194 variant with both increased copy number and constitutive expression of the ermC gene product.
B. subtilis containing plasmid pE194 was grown in medium lacking antibiotic, and 5 x 108 cells were spread onto plates containing 10 ,ug of tylosin (a noninducing macrolide) per ml. Plates were incubated at 30°C, and tylosin-resistant colonies were streaked to single colonies on medium containing 10 jig of tylosin per ml. Plasmid DNA was prepared (34) and analyzed by electrophoresis in agarose gels (6) . One of the resistant strains (tylosin MIC, 16 ig/ml) contained elevated amounts of plasmid DNA and was used to select a constitutive variant as follows. Cells (107) were mixed with soft agar (0.75% agar, wt/vol) and overlaid to agar plates. Several paper disks (6 mm) containing 15 ,ug of tylosin each were applied to the plate, which was incubated at 30°C for 24 h. Colonies which appeared within a clear zone of growth inhibition were picked, streaked to a single colony, and characterized for macrolide resistance. One strain with resistance to >1,000 p.g of tylosin per ml was selected for further study.
Preparation of ribosomes. Cells were grown at 37°C to late log phase, harvested, and washed as described previously (24) Preparation of the in vitro protein synthesis system. Bacteria were grown at 30°C to late log phase, harvested, washed as described for isolation of ribosomes, and frozen at -80°C. Cell pellets were thawed, suspended in buffer A (about 0.5 g [wet weight]/ml), lysed, and processed as described for preparation of ribosomes up to the 30,000 x .g centrifugation. The upper two-thirds of supernatant was removed as the S30 extract and stored in frozen samples at -80°C.
Poly(A) (Sigma Chemical Co.)-directed protein synthesis was conducted as described previously (19) . S30 extract was added to a final concentration of 100 to 300 ,ug of protein per reaction. The final reaction volume was 0.125 ml containing 13 ,uM [14C]lysine (Amersham CFB.69, >11 GBq/mmol), and reactions were started by the addition of poly(A) (100 plg per reaction, final concentration). Duplicate 25-pL samples were removed at 5 and 10 min and added to 0.5 ml of cold 5% trichloroacetic acid containing 100 ,ug of lysine per ml and 0.5 g of tungstic acid (adjusted to pH 2 with NaOH) per liter. Although tungstic acid addition was required to precipitate polylysine peptides efficiently (12), we found that addition of carrier polylysine was not required. Samples were collected on 0.45-,um nitrocellulose filters, washed twice with 5 ml of cold 5% trichloroacetic acid-tungstic acid (0.5 g/liter) solution and once with cold 95% ethanol, dried, and assayed by liquid scintillation counting.
Spermidine optimization was performed by setting up a series of reactions with varied concentrations of spermidine from 0.5 to 10 mM. The spermidine concentration that produced the maximum linear incorporation of radioactivity over 10 min was deemed optimum and was used for subsequent experiments. Inhibition of protein synthesis was assessed by setting up a series of reactions with varied amounts of antibiotic added, preincubating at 37°C for 10 min, and starting reactions by addition of poly(A). Samples were withdrawn at 5 and 10 min. Controls 200 ,ul of buffer was added, and the sample was applied to a linear 10 to 30% (wt/vol) sucrose gradient (12 ml) prepared with the same buffer. Samples were overlaid with light mineral oil and centrifuged for 5 h at 39,000 rpm in a Beckman SW41 rotor at 4°C. Gradients were fractionated from the bottom, and fractions (0.3 to 0.4 ml) were collected. Buffer (0.7 ml) was added, and the A260 per fraction was recorded. The entire fraction was then added to scintillation vials containing 9 ml of InstaGel (United Packard), and radioactivity was determined by liquid scintillation counting. Disintegrations per minute were determined by quench correction and used to calculate picomoles of radiolabeled antibiotic. A,,,) values (22) were used to quantitate the amounts of ribosomal subunits present (1 A260 = 45 pmol of 5OS; 1 A260 = 101 pmol of 30S), and the stoichiometry of macrolide binding to ribosomal subunits was calculated by using these data. Stoichiometry of binding to 70S ribosome complexes (22) was determined by incubating a constant amount of 70S subunits (1 A260 = 31 pmol of 70S) with an increasing amount of macrolide, followed by analysis of the amount of macrolide bound by the filter-binding or spun column method as specified. One molecule of macrolide was found bound per 70S ribosome, or 50S subunit, using the above A26) values.
Analysis of macrolide binding to ribosomes. Parameters of macrolide binding to ribosomes were determined by several methods. The nitrocellulose filter-binding method (26) was used in analysis of macrolide interaction with ribosomes, and competition studies were performed as described previously (32), using 0.6 puM [3H]erythromycin, 0.2 ,uM ribosomes, and incubation for 4 h. Quenching of 3H disintegrations on nitrocellulose filters was determined by flame combustion analysis to 3H20, using a Packard combustion analyzer (United Packard). Since binding of the radiolabeled 6-O-methyl-11,12-cyclic carbamate derivative to nitrocellulose and glass-fiber filters precluded accurate analysis, a spun column method was devised. Sephadex G-50 in 10 mM Tris hydrochloride, pH 7.2, containing 4 mM MgCI2, 100 mM KCl, and 10 mM NH4Cl was packed by centrifugation (1,600 x g for 2 min) into 1-ml disposable syringes fitted with a porous polystyrene disk. Samples (100 p.l) containing ribosomes plus bound and free radiolabeled macrolide were applied to the top of freshly prepared spun columns. Columns were immediately centrifuged for 2 min at 1,600 x g, and the void volume was collected into 1.5-ml Microfuge tubes placed in the bottom of a 15-mI Corex centrifuge tube. Samples from the Microfuge tubes were transferred to scintillation vials, and radioactivity was determined.
The rate of the forward reaction (formation of the macrolide-ribosome complex) was calculated by using the formula 1I(Bo -AO) ln[AO(BO -x)1Bo(Ao -x)] = k1t, where Bo is the concentration of free drug at time zero; AO is the concentration of free ribosomes at time zero; x is the concentration of drug-ribosome complex formed at time t; and k1 is the forward rate constant in molar-' minute-' (14) . This equation describes the forward rate for a second-order reaction, and initial linear rates were used to estimate the rate constant. Ribosome and erythromycin concentrations were reduced to 40 to 60 nM to slow the rate of complex formation. Triplicate 5-ml samples were collected at intervals over a 30-min time period by filtering through 0.45-pum nitrocellulose filters (Millipore Corp.). Excess erythromycin was then added to assure that all ribosomes contained bound erythromycin, thus giving an accurate measure of the total number of ribosomes present. Ribosome and compound la concentrations were in the range of 1 to 2 p.M (0.1-ml volumes), and samples were processed by the spun column procedure (see above).
Rates of dissociation of drug-ribosome complexes were determined by either adding a 50-to 100-fold excess of unlabeled derivative or removing free drug, with subsequent monitoring of ribosome-bound drug with time. The dissociation rate constant was calculated by using the formula ln[(RD)/(RDO)] = -k-1t, where RD0 is the concentration of macrolide-ribosome complex at time zero; RD is the concentration of macrolide-ribosome complex at time t after addition of an excess of unlabeled macrolide; and k-, is the reverse rate conlstant in minute-' (14 Fig. 1 .
RESULTS
Selection of pE194 with increased copy number and constitutive expression of the ermC methylase. We constructed a B.
suibtilis strain which would contain fully dimethylated ribosomes in the absence of any added macrolide for use in our study of macrolide interaction with dimethylated ribosome. This involved selection for a pE194 derivative with elevated copy number as described previously (34 Inhibition of in vitro protein synthesis by 6-0-methyl-11,12-cyclic carbamate derivatives of erythromycin. Certain 6-0-methyl-11,12-cyclic carbamate derivatives (la and lc) were unique in their abilities to inhibit protein synthesis by MLS-resistant ribosomes (Fig. 2) . In contrast, erythromycin (Fig. 2) , tylosin, and niddamycin (data not shown) were completely ineffective at inhibiting protein synthesis by MLS-resistant ribosomes, as expected from the in vivo MIC data ( Table 1) . All of the macrolides tested were able to inhibit in vitro protein synthesis by normal sensitive ribosomes (erythromycin, la, and lc [ Fig. 2 ] and niddamycin and tylosin [data not shown]). In all cases, the degree of inhibition was dose dependent, and la and lc were more potent inhibitors of protein synthesis by sensitive ribosomes compared with MLS-resistant ribosomes. Although these data are consistent with the hypothesis that 6-0-methyl-11,12-cyclic carbamate bind to MLS-resistant ribosomes, inhibiting protein synthesis and thus cell growth, they do not rule out nonspecific effects on in vitro protein synthesis.
Therefore, direct interaction of one 6-0-methyl-11,12-cyclic Binding of erythromycin and la to normal and MLSresistant ribosomes and ribosomal subunits. The radiolabeled 6-0-methyl-11,12-cyclic carbamate derivative, la, interacted specifically with the 50S MLS-resistant ribosomal subunit. Ribosomes (70S) were incubated with an excess of drug, and subunits were dissociated and separated on a sucrose gradient. Radiolabeled drug was bound specifically to the 50S MLS-resistant subunit, not to the 30S subunit, and remaining unbound drug was at the top of the gradient (Fig. 3A) .
Derivative la also bound specifically to the sensitive 50S ribosomal subunit (Fig. 3B) . The stoichiometry of binding to 50S subunits was approximately 1. In contrast, radiolabeled erythromycin did not bind to either the 50S or the 30S MLS-resistant ribosomal subunit (Fig. 4A) , but as expected, did bind to sensitive 50S subunits (Fig. 4B) by similar analysis. Derivative la also bound to both the MLS-resistant ( Fig. 5A ) and -sensitive (not shown) 50S ribosomal subunits isolated from S. aireius, and as expected, erythromycin did not bind to the MLS-resistant 50S (Fig. SB) , but did bind to the sensitive 50S subunit (not shown).
These results were confirmed by using isolated ribosomal subunits from constitutively MLS-resistant B. siibtilis. The traditional filter-binding assay for macrolide interaction with ribosomes was not applicable to studying the interaction of 6-0-methyl-11,12-cyclic carbamate because of nonspecific binding to filters. We therefore developed a spun column procedure for separation of ribosome-bound and free drug. In this case, ribosomes elute in the void volume fraction due to their large size and are quantitatively recovered. In contrast, free drug is included in the column matrix and only trace amounts elute in the void fraction in the absence of ribosomes. The radiolabeled 6-0-methyl-11,12-cyclic carbamate derivative, la, bound specifically to the isolated 50S MLS-resistant ribosomal subunit, and no significant binding was detected to isolated 30S subunits (Fig. 6) ; the slight binding observed with 30S subunits (Fig. 6 ) was due to slight contamination with 50S subunits (data not shown). The stoichiometry of binding to the 50S MLS-resistant ribosomal subunit was estimated at 1.
Additional studies of binding to 70S ribosomal complexes yielded stoichiometries of one macrolide per 70S complex for erythromycin A binding to sensitive ribosomes (filterbinding method) and for la binding to sensitive or MLSresistant ribosomes (spun column method). In contrast, no binding of erythromycin A was observed to MLS-resistant ribosomes (<1 pmol of erythromycin A per 100 pmol of ribosome) by filter binding even when the erythromycin concentration was increased to 40 F.M. At this concentration 10 pmol of erythromycin A was found bound to 100 pmol of 70S complex, using the spun column method. This difference between methods was likely due to the ability of the spun column procedure to detect weaker binding than will the filter-binding method. However, both methods show that erythromycin binds poorly, if at all, to dimethylated ribosomes from B. slubtilis. Compound la was able to compete for the erythromycin-binding site on sensitive ribosomes with a 50% inhibitory concentration (IC50) of 0.8 FM. The 33, 1989 ribosome are nearly identical, as are their MICs for growth 140 p mol 50S inhibition of susceptible B. subtilis (Table 1) and their IC50s for inhibition of in vitro protein synthesis (Fig. 2) . In addition, la had the same IC50 for competition against erythromycin as did erythromycin itself (see above), indicating a similar equilibrium binding affinity. However, as mentioned above (Table 2) , both the forward and the reverse rate constants of la for the sensitive ribosome are drastically different than the rate constants for the parent molecule erythromycin. Although erythromycin does not bind to MLS-resistant ribosomes, la does, and again the rate constants differ dramatically from those characteristic of the 90 p mol 30S erythromycin-sensitive ribosome interaction. In this case, the forward rate constant is even slower for la interaction with the MLS-resistant ribosome than it is for that with the 0 2 4 6 8 1 0 sensitive ribosome. Thus, the Kd is even weaker, as pre-
dicted by the poorer MIC of la on the constitutively MLSresistant B. subtilis strain compared with the susceptible Binding of la to isolated 30 and 50S MLS-resistant strain (Table 1 ) and the higher IC50 for inhibition of in vitro ;ubunits isolated from B. subtilis. Ribosomal subunits protein synthesis from the MLS-resistant strain compared tted on a 15 to 30% linear sucrose gradient, collected by with the susceptible strain (Fig. 2) .
On at 100,000 x g for 3 h, and suspended in ribosomeSelection of macrolide-resistant derivatives from susceptible rer. Subunits (140 pmol of 50S, 90 pmol of 30S) were B. subtilis. Macrolide-resistant derivatives of the susceptible i0.5 ml of buffer containing increasing concentrations of strain BD170 were obtained by plating cells on medium I la for 1 h. Subunits and bound la were collected by containing erythromycin or derivative la. The frequency of on through 1-ml G50 columns. The amount of la bound resistance to both macrolides was identical when selection ined by liquid scintillation counting.
used cells grown from a single colony; however, as expected, this frequency varied when cells from independent rthromycin itself was 0.6 ,uM under the conditions single colonies were used (range, 1 x 10-7 to 5 x 10-9). The .awM [3H]erythromycin, 0.2 ,uM concentrations of MICs of erythromycin and la were 25 and 50 ,ug/ml, respecibosomes, and 4-h incubation at 37°C).
tively, for all resistant mutants tested regardless of which of interaction of macrolides with sensitive and agent was used for selection.
MLS-resistant ribosomes. The kinetics of interaction of the 6-O-methyl-11,12-cyclic carbamate derivative, la, with sensitive or MLS-resistant ribosomes was significantly different than the interaction of its parent structure, erythromycin, with sensitive ribosomes prepared from B. subtilis (Table 2 ). The association rate constant for the la-ribosome complex, using either sensitive or MLS-resistant ribosomes, was several hundredfold slower than formation of the erythromycin-sensitive ribosome complex ( Table 2 ). The dissociation rate constant of the la-ribosome complex, using sensitive or MLS-resistant ribosomes, was also dramatically slower (50-to 100-fold) than the dissociation of the erythromycin-sensitive ribosome complex. Addition of sodium dodecyl sulfate to ribosomes containing bound la, followed by gel electrophoresis, gave no evidence of any covalent (<5%) linkage of la to ribosomal components. We have not acertained whether la released from ribosomes is modified, but have no evidence which suggests that any alterations occur. The Kd for equilibrium binding can be calculated by using the forward and reverse rate constants, k1 and k-1 ( Table 2 ).
The Kd values for erythromycin and la for the sensitive DISCUSSION Compound la, a 6-O-methyl-11,12-cyclic carbamate derivative of erythromycin, binds to dimethylated MLS-resistant ribosomes, inhibiting protein synthesis and thus growth of constitutively MLS-resistant bacteria. We utilized two sets of bacteria (S. epidermidis and B. subtilis) constructed by transformation, and in the case of B. subtilis we constructed a strain which maximally expressed the ermC methylase due to elevated plasmid copy number and constitutive expression. Binding was specific for a single site on the MLSresistant 50S ribosomal subunit isolated from B. subtilis and S. aureus. In contrast, the parent structure, erythromycin, from which compound la was synthetically derived did not bind to MLS-resistant ribosomes or inhibit growth-of constitutively MLS-resistant bacteria. These data are consistent with the hypothesis that la has regained access to the altered macrolide-binding site present on the dimethylated MLSresistant 50S ribosomal subunit. We used ribosomes which were not washed with 1 M NH4Cl for the detailed experiments reported above, because we thought this would more (29) , and our data indicate that this same change is selected by derivative la.
We are only aware of one method in the literature in which the kinetics of macrolide interaction with ribosomes was studied directly (17, 18) , and in this case the macrolide, 9(S)-erythromycylamine, was derivatized with the bulky fluorescent group 5-fluorescein isothiocyanate. In this case, the kinetic constants were altered significantly compared with the parent macrolide. Since the association rate constant had never been directly measured for the parent macrolide erythromycin, but only calculated (13, 26) , we thought it advisable to attempt such direct measurements. We recently devised a procedure to measure the initial rate of formation of the macrolide-ribosome complex directly, allowing calculation of the second-order rate constant for the reaction, by using ribosomes isolated from various gramnegative and gram-positive bacteria (R. Goldman and C. Doran, manuscript in preparation). We have applied this procedure to the analysis of ribosome interaction with the macrolide derivatives described in this report.
The forward rate constant of erythromycin binding to sensitive B. subtilis ribosomes was 4.9 x 107 liters mol-1 min-'; the reverse rate constant was 0.067 min-', yielding a Kd of 1.4 x 10-9 M at equilibrium ( Table 2 ). The value measured directly for k, is significantly greater than values estimated for k, by previous indirect measurements with E.
coli ribosomes (13, 26) ; the Kd value we calculated, using our measured k,1 ( Significant differences were observed between k, and k-, for the interaction of compound la with sensitive and MLS-resistant ribosomes from B. subtilis when compared with the same values measured for the interaction of the parent structure erythromycin with sensitive ribosomes. The association rate constants for compound la binding to both sensitive and MLS-resistant ribosomes is 100-and 500-fold slower, respectively, than the k, value for erythromycin binding to sensitive ribosomes. Since k1 for erythromycin interaction with sensitive ribosomes is of the same order of magnitude as that reported for other receptor-ligand interactions (37), the slower value of k1 for la interaction with both sensitive and MLS-resistant ribosomes shows that the interaction of la with ribosomes is different than that of the parent structure erythromycin and is unique in terms of interaction kinetics. However, interaction with the sensitive ribosome does occur at the macrolide-binding site because (i) la will compete for erythromycin binding to sensitive ribosomes, (ii) selection for resistance to erythromycin or la yields bacteria with identical cross-resistance patterns, and (iii) interaction of la with sensitive ribosomes causes induction of both ermC and ermD regulatory systems (S. Kadam and R. Goldman, manuscript in preparation). This latter observation shows that both la and erythromycin interaction with sensitive B. subtilis ribosomes perturb ribosome function similarly, leading to induction of inducible ermC and ermD regulatory systems. In addition, k-1 is also 50-to 100-fold slower for the dissociation rate constant of the la-ribosome complex compared with the k-1 value for the erythromycin-sensitive ribosome complex. The slow dissociation rate constant of la for sensitive ribosomes also occurs in vivo, leading to a more bactericidal response and to a prolonged postantibiotic effect when compared with the parent structure erythromycin (R. C. Goldman and S. K. Kadam, Program Abstr. 28th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 928, 1988) .
Derivative la appears to interact with ribosomes in a unique manner. Since la interacts at the normal macrolidebinding site on sensitive ribosomes with similar affinity, but with very slow association and dissociation rate constants compared with the parent structure erythromycin, its unique chemical structure must be limiting the rate of complex formation and dissociation at the normal macrolide-binding site. Similarly, association and dissociation rate constants of la for dimethylated MLS-resistant ribosomes are slow, but in this case there is a 10-fold decrease in binding affinity compared with binding to sensitive ribosomes. Although we are pursuing identification of the precise binding site of la on the MLS-resistant ribosome, we as yet have no definitive data demonstrating that binding occurs at a site analogous to the macrolide site on sensitive ribosomes. Chloramphenicol will partially compete for erythromycin binding to sensitive ribosomes, as well as for la binding to MLS-resistant ribosomes, but the high concentrations required do not allow firm conclusions to be drawn (unpublished data).
Dimethylation of adenine 2058 is a rather modest change in ribosome structure, and all of the other structural components of the macrolide-binding site, other ribosomal proteins, and rRNA are still present and functioning normally in MLS-resistant ribosomes (we observe no change in the rate of protein synthesis in vitro [unpublished data]). Thus, it is possible that la regains access to a sequestered or conformationally altered macrolide-binding site which exists on the MLS-resistant ribosome. The aromatic ring introduced into la is required for activity against MLS-resistant organisms (10; unpublished data) and thus plays an important role in binding. This could involve the recently described role of aromatic rings as hydrogen bond acceptors (3-kcal [ca. 12.5 kJ]/mol stabilizing enthalpy) in protein-drug complexes (20) . Our data are most consistent with the hypothesis that la interaction with the MLS-resistant ribosome initiates a conformational change which renders the macrolide-binding site available for ligand interaction, because (i) k1 and k-1 are slow for la interaction with both sensitive and MLS-resis-1065 VOL. 33, 1989 on October 19, 2017 by guest http://aac.asm.org/ Downloaded from 1066 GOLDMAN AND KADAM tant ribosomes, (ii) la interacts at the macrolide-binding site on sensitive ribosomes, (iii) a rate-limiting induced conformational change during complex formation would explain the slow dissociation rate of the complex in terms of the thermodynamics of microscopic reversibility, and (iv) preliminary molecular modeling studies show that the macrolide ring and sugars are in the same conformation in both erythromycin and compound la.
